Peptide-based therapy in lupus: promising data.
Systemic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease of multifactorial aetiology, characterized by inflammation and damage of various tissues and organs. Current treatments of the disease are mainly based on immunosuppressive drugs such as corticosteroids and cyclophosphamide. Although these treatments have reduced mortality and morbidity, they cause a non-specific immune suppression. To avoid these side effects, our efforts should focus on the development of alternative therapeutic strategies, which consist, for example in specific T cell targeting using autoantigen-derived peptides identified as sequences encompassing major epitopes.
Monneaux
Fanny
F
Institut de Biologie Moléculaire et Cellulaire, 67000 Strasbourg, France.
Muller
Sylviane
S
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D001324:Autoantigens / Q000737:chemistry; D001327:Autoimmune Diseases / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D000939:Epitopes; D006801:Humans; D007107:Immune System; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy*; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D001324:Autoantigens; D000939:Epitopes; D007166:Immunosuppressive Agents; D010455:Peptides; D003520:Cyclophosphamide